Guangzhou Bio-gene Technology Co., Ltd
Clinical trials sponsored by Guangzhou Bio-gene Technology Co., Ltd, explained in plain language.
-
New Two-Target cell therapy tested for tough blood cancer
Disease control Not yet recruitingThis early-stage study is testing a new type of CAR-T cell therapy for adults with multiple myeloma that has come back or stopped responding to other treatments. The therapy involves modifying a patient's own immune cells to attack the cancer by targeting two specific markers on …
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Apr 01, 2026 21:56 UTC
-
New 'Living Drug' trial targets Tough-to-Treat blood cancer
Disease control Not yet recruitingThis early-stage study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy for people with relapsed or refractory multiple myeloma. The therapy involves collecting a patient's own immune cells, modifying them in a lab to target two proteins on myel…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New 'Living Drug' trial targets tough blood cancers
Disease control Not yet recruitingThis early-stage study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy called BAFFR CAR-T in adults with B-cell leukemia or lymphoma that has come back or not responded to standard treatments. Doctors will give the therapy to a small group of p…
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC